Literature DB >> 34855111

Development of a 48-Well Dynamic Suspension Culture System for Pancreatic Differentiation from Human Embryonic Stem Cells.

Yizhe Song1, Xiaoqian Chen2, Decan Liang2, Jing Liu2, Jingqiu Li2, Zhensheng Ou2, Tingting Tang2, Peiwen Xing2, Leilei Guo2, Shidu Zhang2, Qunrui Ye2, Wenjia Li3, Yinghua Chen4, Xiuli Wang5.   

Abstract

BACKGROUND: Human pluripotent stem cells (hPSCs) have started to emerge as a potential tool with application in fields of drug discovery, disease modelling and cell therapy. A variety of protocols for culturing and differentiating pluripotent stem cells into pancreatic β like cells have been published. However, small-scale dynamic suspension culture systems, which could be applied toward systematically optimizing production strategies for cell replacement therapies to accelerate the pace of their discovery and development toward the clinic, are overlooked.
METHODS: Human embryonic stem cell (hESC) line H9 was used to establish the novel 48-well dynamic suspension culture system. The effects of various rotational speeds and culture medium volumes on cell morphology, cell proliferation, cell viability and cell phenotype were evaluated. Effect of cell density on the pancreatic differentiation efficiency from H9 cells in 48-well plates was further investigated. In vitro the function of pancreatic β like cells was assessed by measuring glucose-stimulated insulin secretion. MAIN
RESULTS: A 48-well dynamic suspension culture system for hESC expansion as cell aggregates was developed. With optimized rotational speed and culture medium volume, hESCs maintained normal karyotype, viability and pluripotency. Furthermore, the system can also support the hESC aggregates subsequent differentiation into functional pancreatic β like cells after optimizing initial cell seeding density.
CONCLUSION: A controllable 48-well suspension culture system in microplates for hESCs maintenance, expansion and pancreatic differentiation was developed, which may provide an efficient platform for high-throughput drug screening.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Differentiation; Dynamic suspension culture; Embryonic stem cells; Pancreatic β like cells; Pluripotent stem cells

Mesh:

Year:  2021        PMID: 34855111     DOI: 10.1007/s12015-021-10312-w

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   6.692


  23 in total

1.  How iPS cells changed the world.

Authors:  Megan Scudellari
Journal:  Nature       Date:  2016-06-16       Impact factor: 49.962

Review 2.  Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges.

Authors:  Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2020-10-01       Impact factor: 24.633

Review 3.  Induced pluripotent stem cell technology: a decade of progress.

Authors:  Yanhong Shi; Haruhisa Inoue; Joseph C Wu; Shinya Yamanaka
Journal:  Nat Rev Drug Discov       Date:  2016-12-16       Impact factor: 84.694

4.  Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen.

Authors:  Uri Ben-David; Qing-Fen Gan; Tamar Golan-Lev; Payal Arora; Ofra Yanuka; Yifat S Oren; Alicia Leikin-Frenkel; Martin Graf; Ralph Garippa; Markus Boehringer; Gianni Gromo; Nissim Benvenisty
Journal:  Cell Stem Cell       Date:  2013-01-11       Impact factor: 24.633

5.  Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study.

Authors:  Adrian J C Bloor; Amit Patel; James E Griffin; Maria H Gilleece; Rohini Radia; David T Yeung; Diana Drier; Laurie S Larson; Gene I Uenishi; Derek Hei; Kilian Kelly; Igor Slukvin; John E J Rasko
Journal:  Nat Med       Date:  2020-09-14       Impact factor: 53.440

Review 6.  Pluripotent stem cells in disease modelling and drug discovery.

Authors:  Yishai Avior; Ido Sagi; Nissim Benvenisty
Journal:  Nat Rev Mol Cell Biol       Date:  2016-01-28       Impact factor: 94.444

Review 7.  The promise of induced pluripotent stem cells in research and therapy.

Authors:  Daisy A Robinton; George Q Daley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

8.  Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients.

Authors:  Won Kyung Song; Kyung-Mi Park; Hyun-Ju Kim; Jae Ho Lee; Jinjung Choi; So Young Chong; Sung Han Shim; Lucian V Del Priore; Robert Lanza
Journal:  Stem Cell Reports       Date:  2015-04-30       Impact factor: 7.765

9.  Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation.

Authors:  Miguel Cardoso de Brito; Pedro Madrigal; Nicholas R F Hannan; Ludovic Vallier; Fotios Sampaziotis; Alessandro Bertero; Kourosh Saeb-Parsy; Filipa A C Soares; Elisabeth Schrumpf; Espen Melum; Tom H Karlsen; J Andrew Bradley; William Th Gelson; Susan Davies; Alastair Baker; Arthur Kaser; Graeme J Alexander
Journal:  Nat Biotechnol       Date:  2015-07-13       Impact factor: 54.908

10.  Large-Scale Production of Mature Neurons from Human Pluripotent Stem Cells in a Three-Dimensional Suspension Culture System.

Authors:  Alessandra Rigamonti; Giuliana G Repetti; Chicheng Sun; Feodor D Price; Danielle C Reny; Francesca Rapino; Karen Weisinger; Chen Benkler; Quinn P Peterson; Lance S Davidow; Emil M Hansson; Lee L Rubin
Journal:  Stem Cell Reports       Date:  2016-06-14       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.